Evidence map›Paper›PMID 35956979›Full record

ArticleMolecules (Basel, Switzerland)2022

Identification of Novel 4'-

Wenli Xi, Hua Sun, Kenneth F Bastow, Zhiyan Xiao, Kuo-Hsiung Lee

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 3 countries.

Wenli XiBeijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Hua SunThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Material Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Kenneth F BastowNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, USA.
Zhiyan XiaoBeijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Kuo-Hsiung LeeNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, USA.ORCID 0000-0002-6562-0070
Chinese Academy of Medical Sciences & Peking Union Medical College · CNUniversity of North Carolina at Chapel Hill · US

Funding

Chinese Academy of Medical Sciences 2016-I2M-3-009
6 · The paper itself

Abstract

C4 variation of 4'-

Indexed as

Antineoplastic AgentsPodophyllotoxinAnimalsDNA Topoisomerases, Type IIDrug Screening Assays, AntitumorMiceStructure-Activity RelationshipTopoisomerase II InhibitorsAntineoplastic AgentsDNA Topoisomerases, Type IIPodophyllotoxinTopoisomerase II Inhibitors4′-O-demethyl-epipodophyllotoxinantitumor agenttopoisomerase II

Identifiers

PMID35956979
PMCPMC9370175
OpenAlexW4292451822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.